Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD5004

Exclusion Criteria

• •For ALL participants:
• •Poorly controlled diabetes mellitus (A1C \>10% at screening).
• •Unwillingness to use adequate contraception
• •Uncontrolled hypertension or hypotension
• •Presence of unstable systemic disease or psychologic conditions.
• •Any clinically significant abnormalities in rhythm, conduction, or morphology of the resting ECG and any clinically important abnormalities in the 12-lead ECG.
• •Specific For Healthy Controls:
• •Positive screening for HIV, Hepatitis B, or Hepatitis C -
• •Any clinically significant disease or disorder to include but not limited to acute or chronic liver disease
• •Specific For Hepatically Impaired Participants:
• •eGFR \<60 ml/min/1.73 m2
• •Fluctuating or rapidly deteriorating hepatic function, as indicated by strongly varying or worsening of clinical and/or laboratory signs of hepatic impairment to include rising LFTs, paracentesis at less than 4 week intervals, oesophageal banding within the last 3 months, or treatment for GI bleeding within the last 6 months
• •Presence of a hepatocellular carcinoma or acute liver disease caused by an infection or drug toxicity.